| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 50 | 2025 | 863 | 4.580 |
Why?
|
| Heart Failure | 29 | 2023 | 2173 | 1.870 |
Why?
|
| Graft Rejection | 18 | 2025 | 553 | 1.700 |
Why?
|
| Heart-Assist Devices | 22 | 2022 | 1032 | 1.610 |
Why?
|
| Graft Survival | 9 | 2025 | 455 | 0.880 |
Why?
|
| Natriuretic Peptide, Brain | 6 | 2009 | 277 | 0.880 |
Why?
|
| Cardiomyopathies | 11 | 2022 | 493 | 0.830 |
Why?
|
| Ventricular Dysfunction, Left | 9 | 2017 | 351 | 0.760 |
Why?
|
| Child | 78 | 2025 | 25061 | 0.700 |
Why?
|
| Kidney Transplantation | 2 | 2021 | 561 | 0.660 |
Why?
|
| Child, Preschool | 56 | 2025 | 14330 | 0.650 |
Why?
|
| Retrospective Studies | 53 | 2023 | 16768 | 0.580 |
Why?
|
| Adolescent | 59 | 2025 | 19936 | 0.560 |
Why?
|
| Cardiomyopathy, Dilated | 8 | 2022 | 208 | 0.540 |
Why?
|
| Infant | 44 | 2025 | 12762 | 0.530 |
Why?
|
| Postoperative Complications | 12 | 2025 | 2967 | 0.500 |
Why?
|
| Death, Sudden, Cardiac | 6 | 2020 | 270 | 0.480 |
Why?
|
| Cardiomyopathy, Hypertrophic | 6 | 2016 | 154 | 0.460 |
Why?
|
| Risk Assessment | 6 | 2019 | 3460 | 0.440 |
Why?
|
| Immunosuppressive Agents | 4 | 2025 | 650 | 0.440 |
Why?
|
| Tissue and Organ Procurement | 2 | 2023 | 239 | 0.420 |
Why?
|
| Myocardium | 6 | 2013 | 839 | 0.420 |
Why?
|
| Male | 70 | 2025 | 62073 | 0.410 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2021 | 1025 | 0.410 |
Why?
|
| Kidney Failure, Chronic | 1 | 2021 | 923 | 0.410 |
Why?
|
| Anemia, Iron-Deficiency | 3 | 2021 | 136 | 0.410 |
Why?
|
| Female | 71 | 2025 | 67899 | 0.410 |
Why?
|
| Treatment Outcome | 27 | 2025 | 12315 | 0.400 |
Why?
|
| Humans | 93 | 2025 | 126057 | 0.370 |
Why?
|
| Cardiac Output, Low | 3 | 2007 | 61 | 0.330 |
Why?
|
| Histocompatibility Testing | 1 | 2010 | 106 | 0.320 |
Why?
|
| Heart Failure, Systolic | 2 | 2021 | 32 | 0.320 |
Why?
|
| Extracorporeal Membrane Oxygenation | 5 | 2019 | 667 | 0.320 |
Why?
|
| Isolated Noncompaction of the Ventricular Myocardium | 3 | 2015 | 42 | 0.310 |
Why?
|
| Hospitalization | 10 | 2022 | 1838 | 0.300 |
Why?
|
| HLA Antigens | 1 | 2010 | 217 | 0.300 |
Why?
|
| Antibodies | 1 | 2010 | 351 | 0.300 |
Why?
|
| Registries | 5 | 2021 | 1476 | 0.290 |
Why?
|
| Predictive Value of Tests | 10 | 2017 | 2180 | 0.280 |
Why?
|
| Immunocompromised Host | 2 | 2020 | 302 | 0.280 |
Why?
|
| Stroke Volume | 7 | 2017 | 490 | 0.280 |
Why?
|
| Proportional Hazards Models | 5 | 2019 | 1350 | 0.280 |
Why?
|
| Cardiomyopathy, Restrictive | 2 | 2020 | 22 | 0.280 |
Why?
|
| Heart Defects, Congenital | 5 | 2022 | 1843 | 0.270 |
Why?
|
| Myocarditis | 4 | 2015 | 124 | 0.270 |
Why?
|
| Cohort Studies | 16 | 2021 | 4920 | 0.270 |
Why?
|
| Glomerular Filtration Rate | 2 | 2021 | 533 | 0.270 |
Why?
|
| Infant, Newborn | 18 | 2022 | 8357 | 0.260 |
Why?
|
| Ventricular Function, Left | 5 | 2022 | 504 | 0.260 |
Why?
|
| Organ Transplantation | 2 | 2020 | 174 | 0.250 |
Why?
|
| Renal Insufficiency | 2 | 2015 | 237 | 0.240 |
Why?
|
| Everolimus | 1 | 2025 | 48 | 0.230 |
Why?
|
| Mycophenolic Acid | 1 | 2025 | 57 | 0.230 |
Why?
|
| Tacrolimus | 1 | 2025 | 99 | 0.230 |
Why?
|
| Hospitals, Pediatric | 5 | 2018 | 776 | 0.230 |
Why?
|
| Biopsy | 6 | 2023 | 1233 | 0.220 |
Why?
|
| Arginine Vasopressin | 1 | 2004 | 25 | 0.210 |
Why?
|
| Risk Factors | 15 | 2020 | 10393 | 0.210 |
Why?
|
| Hospital Charges | 2 | 2015 | 64 | 0.210 |
Why?
|
| Heart | 5 | 2022 | 646 | 0.200 |
Why?
|
| Incidental Findings | 1 | 2024 | 119 | 0.200 |
Why?
|
| Tachycardia, Ventricular | 3 | 2016 | 254 | 0.200 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 2 | 2022 | 25 | 0.200 |
Why?
|
| Parvoviridae Infections | 3 | 2013 | 34 | 0.200 |
Why?
|
| Prosthesis Implantation | 2 | 2017 | 151 | 0.200 |
Why?
|
| Survival Rate | 6 | 2021 | 2060 | 0.200 |
Why?
|
| Echocardiography, Doppler | 3 | 2015 | 164 | 0.190 |
Why?
|
| Heart Diseases | 3 | 2013 | 486 | 0.180 |
Why?
|
| Educational Status | 2 | 2020 | 274 | 0.180 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2022 | 77 | 0.180 |
Why?
|
| Thrombosis | 2 | 2022 | 500 | 0.180 |
Why?
|
| Coronary Artery Disease | 4 | 2015 | 818 | 0.180 |
Why?
|
| Probability | 2 | 2019 | 297 | 0.170 |
Why?
|
| Young Adult | 12 | 2023 | 9617 | 0.170 |
Why?
|
| Tissue Donors | 4 | 2024 | 486 | 0.170 |
Why?
|
| Prognosis | 8 | 2019 | 4708 | 0.170 |
Why?
|
| Protein-Losing Enteropathies | 1 | 2020 | 19 | 0.160 |
Why?
|
| Heart Valve Diseases | 1 | 2021 | 165 | 0.160 |
Why?
|
| Cardiac Catheterization | 7 | 2023 | 619 | 0.160 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2024 | 283 | 0.160 |
Why?
|
| Cardiac Rehabilitation | 1 | 2020 | 29 | 0.160 |
Why?
|
| Incidence | 9 | 2025 | 3213 | 0.160 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 204 | 0.160 |
Why?
|
| Myocardial Contraction | 2 | 2020 | 235 | 0.160 |
Why?
|
| Age Factors | 8 | 2021 | 2771 | 0.150 |
Why?
|
| Bilirubin | 1 | 2019 | 124 | 0.150 |
Why?
|
| Cardiac Output | 2 | 2012 | 159 | 0.150 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2019 | 103 | 0.150 |
Why?
|
| Overweight | 1 | 2021 | 370 | 0.150 |
Why?
|
| Troponin T | 1 | 2020 | 218 | 0.140 |
Why?
|
| Perioperative Care | 1 | 2020 | 210 | 0.140 |
Why?
|
| Pulmonary Artery | 3 | 2015 | 445 | 0.140 |
Why?
|
| Exercise Therapy | 1 | 2020 | 172 | 0.140 |
Why?
|
| Allografts | 2 | 2017 | 184 | 0.140 |
Why?
|
| Coronary Vessels | 3 | 2024 | 507 | 0.140 |
Why?
|
| Tracheostomy | 1 | 2020 | 214 | 0.140 |
Why?
|
| Shock, Cardiogenic | 2 | 2018 | 171 | 0.140 |
Why?
|
| Transplant Recipients | 1 | 2019 | 230 | 0.140 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2016 | 108 | 0.130 |
Why?
|
| Multivariate Analysis | 7 | 2019 | 1349 | 0.130 |
Why?
|
| Echocardiography | 4 | 2018 | 1097 | 0.130 |
Why?
|
| Surgical Fixation Devices | 1 | 2017 | 3 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 3256 | 0.130 |
Why?
|
| Pectus Carinatum | 1 | 2017 | 5 | 0.130 |
Why?
|
| Titanium | 1 | 2017 | 22 | 0.130 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2020 | 269 | 0.130 |
Why?
|
| Natriuretic Agents | 2 | 2007 | 22 | 0.130 |
Why?
|
| Anthracyclines | 1 | 2017 | 43 | 0.130 |
Why?
|
| Logistic Models | 1 | 2021 | 1744 | 0.130 |
Why?
|
| Wound Closure Techniques | 1 | 2017 | 27 | 0.130 |
Why?
|
| Heart Ventricles | 2 | 2018 | 750 | 0.130 |
Why?
|
| Nitric Oxide | 1 | 2019 | 463 | 0.130 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2017 | 51 | 0.130 |
Why?
|
| Parvovirus B19, Human | 3 | 2013 | 26 | 0.120 |
Why?
|
| DNA, Viral | 3 | 2013 | 449 | 0.120 |
Why?
|
| Respiration, Artificial | 1 | 2019 | 486 | 0.120 |
Why?
|
| Loeys-Dietz Syndrome | 1 | 2017 | 40 | 0.120 |
Why?
|
| Adult | 16 | 2023 | 30253 | 0.120 |
Why?
|
| Clostridium Infections | 1 | 2019 | 242 | 0.120 |
Why?
|
| Hospital Mortality | 3 | 2020 | 976 | 0.120 |
Why?
|
| Oxygen | 1 | 2019 | 540 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2016 | 32 | 0.120 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2017 | 123 | 0.120 |
Why?
|
| Gadolinium DTPA | 1 | 2016 | 47 | 0.120 |
Why?
|
| Atrial Function, Right | 1 | 2015 | 9 | 0.120 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2015 | 49 | 0.120 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1131 | 0.120 |
Why?
|
| Hyponatremia | 1 | 2016 | 73 | 0.120 |
Why?
|
| Ventricular Pressure | 1 | 2015 | 36 | 0.110 |
Why?
|
| Follow-Up Studies | 10 | 2018 | 5050 | 0.110 |
Why?
|
| Device Removal | 1 | 2017 | 216 | 0.110 |
Why?
|
| Ventricular Dysfunction | 1 | 2015 | 25 | 0.110 |
Why?
|
| Anemia | 1 | 2018 | 336 | 0.110 |
Why?
|
| Sirolimus | 1 | 2016 | 223 | 0.110 |
Why?
|
| Liver Transplantation | 2 | 2021 | 1100 | 0.110 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2016 | 170 | 0.110 |
Why?
|
| Heart Arrest | 2 | 2017 | 359 | 0.110 |
Why?
|
| Mortality | 1 | 2016 | 249 | 0.110 |
Why?
|
| Thermodilution | 2 | 2012 | 13 | 0.110 |
Why?
|
| Renal Dialysis | 1 | 2021 | 928 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2006 | 2022 | 0.100 |
Why?
|
| Aorta | 1 | 2017 | 498 | 0.100 |
Why?
|
| Endocardium | 1 | 2013 | 44 | 0.100 |
Why?
|
| Severity of Illness Index | 5 | 2020 | 2936 | 0.100 |
Why?
|
| Neuropsychological Tests | 1 | 2016 | 952 | 0.100 |
Why?
|
| Waiting Lists | 1 | 2014 | 236 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2022 | 1757 | 0.090 |
Why?
|
| United States | 8 | 2021 | 11200 | 0.090 |
Why?
|
| Ultrasonography | 3 | 2012 | 934 | 0.090 |
Why?
|
| Hemodynamics | 4 | 2022 | 799 | 0.090 |
Why?
|
| Health Care Costs | 1 | 2015 | 383 | 0.090 |
Why?
|
| Dextrocardia | 1 | 2012 | 8 | 0.090 |
Why?
|
| Candidiasis | 1 | 2013 | 108 | 0.090 |
Why?
|
| Pseudomonas Infections | 1 | 2013 | 109 | 0.090 |
Why?
|
| Arrhythmias, Cardiac | 4 | 2022 | 474 | 0.090 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2011 | 27 | 0.090 |
Why?
|
| Heart, Artificial | 1 | 2012 | 63 | 0.090 |
Why?
|
| Sarcomeres | 2 | 2022 | 32 | 0.090 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 867 | 0.090 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2016 | 523 | 0.090 |
Why?
|
| Transposition of Great Vessels | 1 | 2012 | 118 | 0.080 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 273 | 0.080 |
Why?
|
| Tachycardia | 2 | 2013 | 72 | 0.080 |
Why?
|
| Diastole | 3 | 2020 | 168 | 0.080 |
Why?
|
| Time Factors | 5 | 2018 | 6007 | 0.080 |
Why?
|
| Biomarkers | 3 | 2009 | 3138 | 0.080 |
Why?
|
| Genome, Viral | 1 | 2010 | 153 | 0.080 |
Why?
|
| Monitoring, Physiologic | 1 | 2012 | 369 | 0.080 |
Why?
|
| Sensitivity and Specificity | 3 | 2012 | 2027 | 0.080 |
Why?
|
| Systole | 2 | 2006 | 186 | 0.070 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 1730 | 0.070 |
Why?
|
| Pacemaker, Artificial | 2 | 2017 | 184 | 0.070 |
Why?
|
| Isoantibodies | 1 | 2008 | 62 | 0.070 |
Why?
|
| Virus Diseases | 1 | 2011 | 267 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2021 | 1649 | 0.070 |
Why?
|
| Immunoassay | 1 | 2008 | 125 | 0.070 |
Why?
|
| Staphylococcal Infections | 1 | 2013 | 556 | 0.070 |
Why?
|
| Adenosine Triphosphate | 1 | 2008 | 268 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2010 | 826 | 0.070 |
Why?
|
| Electrocardiography | 3 | 2012 | 918 | 0.070 |
Why?
|
| Databases, Factual | 3 | 2017 | 1175 | 0.070 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 214 | 0.070 |
Why?
|
| Length of Stay | 3 | 2019 | 1324 | 0.070 |
Why?
|
| Cachexia | 1 | 2007 | 49 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2019 | 3303 | 0.070 |
Why?
|
| Transplantation Immunology | 1 | 2007 | 42 | 0.070 |
Why?
|
| Pulse | 1 | 2006 | 25 | 0.060 |
Why?
|
| Prospective Studies | 7 | 2017 | 6090 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2008 | 415 | 0.060 |
Why?
|
| Ticlopidine | 1 | 2006 | 26 | 0.060 |
Why?
|
| Infusions, Parenteral | 1 | 2006 | 78 | 0.060 |
Why?
|
| Milrinone | 1 | 2006 | 30 | 0.060 |
Why?
|
| Glycogen Storage Disease Type IIb | 1 | 2005 | 6 | 0.060 |
Why?
|
| Leukopenia | 1 | 2005 | 43 | 0.060 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2007 | 179 | 0.060 |
Why?
|
| Tertiary Care Centers | 2 | 2019 | 246 | 0.060 |
Why?
|
| Reference Values | 1 | 2006 | 677 | 0.060 |
Why?
|
| Codon, Nonsense | 1 | 2005 | 139 | 0.060 |
Why?
|
| Cardiotonic Agents | 1 | 2006 | 132 | 0.060 |
Why?
|
| Dopamine | 1 | 2006 | 247 | 0.060 |
Why?
|
| Outpatients | 1 | 2006 | 254 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2006 | 195 | 0.060 |
Why?
|
| Coronary Stenosis | 1 | 2005 | 74 | 0.050 |
Why?
|
| Cause of Death | 1 | 2007 | 473 | 0.050 |
Why?
|
| Leukocytes | 1 | 2005 | 203 | 0.050 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2025 | 217 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2008 | 477 | 0.050 |
Why?
|
| Disease Progression | 4 | 2016 | 2099 | 0.050 |
Why?
|
| Pulmonary Circulation | 1 | 2004 | 114 | 0.050 |
Why?
|
| Cytomegalovirus Infections | 1 | 2025 | 217 | 0.050 |
Why?
|
| Obesity | 2 | 2021 | 2330 | 0.050 |
Why?
|
| Prevalence | 3 | 2018 | 2578 | 0.050 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2012 | 1124 | 0.050 |
Why?
|
| Comorbidity | 3 | 2015 | 1537 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2006 | 392 | 0.050 |
Why?
|
| Patient Selection | 1 | 2006 | 702 | 0.050 |
Why?
|
| Chlorides | 1 | 2022 | 98 | 0.050 |
Why?
|
| Hirudins | 1 | 2022 | 35 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2025 | 1135 | 0.050 |
Why?
|
| Mass Screening | 1 | 2008 | 805 | 0.050 |
Why?
|
| Antithrombins | 1 | 2022 | 46 | 0.050 |
Why?
|
| Catheter Ablation | 1 | 2005 | 303 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2025 | 1593 | 0.050 |
Why?
|
| Actin Cytoskeleton | 1 | 2022 | 48 | 0.050 |
Why?
|
| Prosthesis Design | 2 | 2017 | 585 | 0.050 |
Why?
|
| Cytokines | 1 | 2008 | 1312 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 280 | 0.050 |
Why?
|
| Transferrin | 1 | 2021 | 45 | 0.050 |
Why?
|
| Diuretics | 1 | 2022 | 140 | 0.050 |
Why?
|
| Critical Care | 1 | 2007 | 661 | 0.050 |
Why?
|
| Thinness | 1 | 2021 | 69 | 0.040 |
Why?
|
| Sodium | 1 | 2022 | 274 | 0.040 |
Why?
|
| Hemolysis | 1 | 2021 | 102 | 0.040 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2016 | 62 | 0.040 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2022 | 225 | 0.040 |
Why?
|
| Heparin | 1 | 2022 | 202 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2021 | 268 | 0.040 |
Why?
|
| Cytoskeletal Proteins | 1 | 2022 | 273 | 0.040 |
Why?
|
| Tachycardia, Paroxysmal | 1 | 2020 | 10 | 0.040 |
Why?
|
| Aorta, Thoracic | 1 | 2024 | 465 | 0.040 |
Why?
|
| Recurrence | 2 | 2019 | 1399 | 0.040 |
Why?
|
| Recovery of Function | 2 | 2017 | 428 | 0.040 |
Why?
|
| Texas | 3 | 2016 | 3532 | 0.040 |
Why?
|
| Muscle Proteins | 1 | 2022 | 397 | 0.040 |
Why?
|
| Cytoskeleton | 1 | 2020 | 167 | 0.040 |
Why?
|
| Aortic Valve | 1 | 2021 | 411 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2022 | 1294 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2022 | 472 | 0.040 |
Why?
|
| Unnecessary Procedures | 1 | 2019 | 58 | 0.040 |
Why?
|
| Iron | 1 | 2021 | 295 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2022 | 745 | 0.040 |
Why?
|
| Fontan Procedure | 1 | 2020 | 187 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2022 | 563 | 0.030 |
Why?
|
| Exercise Test | 2 | 2011 | 239 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2025 | 795 | 0.030 |
Why?
|
| Wechsler Scales | 1 | 2016 | 19 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1095 | 0.030 |
Why?
|
| Cardiotoxicity | 1 | 2017 | 40 | 0.030 |
Why?
|
| Intelligence Tests | 1 | 2016 | 59 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2017 | 252 | 0.030 |
Why?
|
| Stroke | 2 | 2015 | 1005 | 0.030 |
Why?
|
| Computed Tomography Angiography | 1 | 2017 | 203 | 0.030 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2017 | 249 | 0.030 |
Why?
|
| Heart Septum | 1 | 2015 | 46 | 0.030 |
Why?
|
| Vascular Patency | 1 | 2015 | 176 | 0.030 |
Why?
|
| United Kingdom | 1 | 2015 | 237 | 0.030 |
Why?
|
| Child Behavior | 1 | 2016 | 233 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2009 | 1476 | 0.030 |
Why?
|
| Stents | 1 | 2020 | 735 | 0.030 |
Why?
|
| Vascular Resistance | 1 | 2015 | 185 | 0.030 |
Why?
|
| Arterial Pressure | 1 | 2015 | 123 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2003 | 2341 | 0.030 |
Why?
|
| Child Development | 1 | 2016 | 265 | 0.030 |
Why?
|
| Syndrome | 2 | 2008 | 1132 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 672 | 0.030 |
Why?
|
| Algorithms | 2 | 2011 | 1615 | 0.030 |
Why?
|
| Mothers | 1 | 2016 | 363 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2016 | 1065 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 2015 | 237 | 0.030 |
Why?
|
| Pseudomonas | 1 | 2013 | 10 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 1188 | 0.020 |
Why?
|
| Mitral Valve | 1 | 2015 | 248 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 529 | 0.020 |
Why?
|
| Staphylococcus | 1 | 2013 | 67 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2015 | 442 | 0.020 |
Why?
|
| Atrial Flutter | 1 | 2013 | 44 | 0.020 |
Why?
|
| Contrast Media | 1 | 2016 | 459 | 0.020 |
Why?
|
| Candida | 1 | 2013 | 80 | 0.020 |
Why?
|
| Infant Mortality | 1 | 2013 | 177 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2019 | 777 | 0.020 |
Why?
|
| Sternotomy | 1 | 2012 | 36 | 0.020 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2012 | 76 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 757 | 0.020 |
Why?
|
| Cognition | 1 | 2016 | 783 | 0.020 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2012 | 76 | 0.020 |
Why?
|
| Coxsackievirus Infections | 1 | 2010 | 10 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2015 | 443 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2013 | 613 | 0.020 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2012 | 141 | 0.020 |
Why?
|
| Genotype | 1 | 2016 | 2600 | 0.020 |
Why?
|
| Adenoviridae Infections | 1 | 2010 | 68 | 0.020 |
Why?
|
| Enterovirus | 1 | 2010 | 52 | 0.020 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2012 | 362 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2013 | 556 | 0.020 |
Why?
|
| Body Weight | 1 | 2013 | 969 | 0.020 |
Why?
|
| Medical Records | 1 | 2009 | 177 | 0.020 |
Why?
|
| Patient Safety | 1 | 2013 | 434 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2868 | 0.020 |
Why?
|
| Acute Disease | 1 | 2011 | 1046 | 0.020 |
Why?
|
| Assisted Circulation | 1 | 2007 | 35 | 0.020 |
Why?
|
| Interleukin-18 | 1 | 2008 | 65 | 0.020 |
Why?
|
| Diuresis | 1 | 2007 | 45 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2008 | 130 | 0.020 |
Why?
|
| Renin | 1 | 2007 | 73 | 0.020 |
Why?
|
| Hypotension | 1 | 2009 | 178 | 0.020 |
Why?
|
| Endothelin-1 | 1 | 2007 | 38 | 0.020 |
Why?
|
| Aldosterone | 1 | 2007 | 57 | 0.020 |
Why?
|
| Sepsis | 1 | 2012 | 490 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2008 | 150 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2010 | 573 | 0.020 |
Why?
|
| Norepinephrine | 1 | 2007 | 152 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2750 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 1486 | 0.020 |
Why?
|
| Heart Function Tests | 1 | 2006 | 49 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2007 | 237 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2010 | 627 | 0.020 |
Why?
|
| Defibrillators, Implantable | 1 | 2009 | 209 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2008 | 403 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 418 | 0.020 |
Why?
|
| Equipment Failure | 1 | 2006 | 128 | 0.020 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 1 | 2005 | 10 | 0.010 |
Why?
|
| Inflammation | 1 | 2013 | 1417 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2008 | 518 | 0.010 |
Why?
|
| Papillary Muscles | 1 | 2005 | 18 | 0.010 |
Why?
|
| Creatinine | 1 | 2007 | 378 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 638 | 0.010 |
Why?
|
| Warfarin | 1 | 2006 | 112 | 0.010 |
Why?
|
| Drug Overdose | 1 | 2006 | 71 | 0.010 |
Why?
|
| Mice | 1 | 2022 | 17574 | 0.010 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 2005 | 73 | 0.010 |
Why?
|
| ROC Curve | 1 | 2006 | 572 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2005 | 412 | 0.010 |
Why?
|
| Aspirin | 1 | 2006 | 202 | 0.010 |
Why?
|
| Patient Admission | 1 | 2006 | 170 | 0.010 |
Why?
|
| Muscular Diseases | 1 | 2005 | 116 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 525 | 0.010 |
Why?
|
| Heart Rate | 1 | 2007 | 565 | 0.010 |
Why?
|
| Medical Errors | 1 | 2006 | 152 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2026 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 2003 | 63 | 0.010 |
Why?
|
| Mitochondrial Myopathies | 1 | 2003 | 28 | 0.010 |
Why?
|
| Acyltransferases | 1 | 2003 | 62 | 0.010 |
Why?
|
| Bradycardia | 1 | 2004 | 55 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2005 | 738 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2004 | 232 | 0.010 |
Why?
|
| Exercise Tolerance | 1 | 2004 | 87 | 0.010 |
Why?
|
| Chest Pain | 1 | 2004 | 93 | 0.010 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2004 | 84 | 0.010 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2003 | 114 | 0.010 |
Why?
|
| Exercise | 1 | 2009 | 837 | 0.010 |
Why?
|
| Ultrasonography, Doppler | 1 | 2004 | 181 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2004 | 299 | 0.010 |
Why?
|
| Abdominal Pain | 1 | 2005 | 306 | 0.010 |
Why?
|
| Resuscitation | 1 | 2005 | 268 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 2547 | 0.010 |
Why?
|
| Animals | 1 | 2022 | 33105 | 0.010 |
Why?
|
| Kidney | 1 | 2007 | 1279 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 979 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2005 | 2390 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2006 | 1025 | 0.010 |
Why?
|
| Proteins | 1 | 2003 | 1016 | 0.010 |
Why?
|